Cardio Diagnostics Awaits CMS Decision on Medicare Pricing for Heart Disease Tests
TL;DR
Cardio Diagnostics is awaiting a crucial decision that could be a major factor in the commercial success of its flagship heart disease tests.
The company attended a meeting hosted by the Centers for Medicare and Medicaid Services (CMS) to present pricing recommendations for its two cutting-edge tests: Epi+Gen CHD and PrecisionCHD.
Cardio Diagnostics' advanced diagnostic tools have the potential to bring its heart disease tests one step closer to being widely accessible to Medicare patients, potentially saving the lives of millions.
Cardio Diagnostics' AI-powered blood-based DNA test, Epi+Gen CHD, evaluates genetic and epigenetic markers to assess the three-year risk for a symptomatic CHD event.
Found this article helpful?
Share it with your network and spread the knowledge!
Cardio Diagnostics (NASDAQ: CDIO), a company specializing in AI-driven cardiovascular disease prevention, is on the verge of a potentially transformative moment as it awaits the Centers for Medicare and Medicaid Services (CMS) decision on Medicare pricing for its innovative heart disease tests. The CMS is expected to release its proposed payment determinations this month, following Cardio Diagnostics' presentation at the annual CMS meeting in June.
The company's two flagship tests, Epi+Gen CHD and PrecisionCHD, represent significant advancements in the prevention, detection, and management of coronary heart disease (CHD). These AI-powered blood-based DNA tests evaluate genetic and epigenetic markers to assess CHD risk and aid in diagnosis. Both tests have already received unique CPT codes from the American Medical Association, effective April 2024, marking an important step towards widespread adoption.
The CMS decision holds substantial implications for both Cardio Diagnostics and the broader healthcare landscape. Heart disease remains the leading cause of death among Medicare beneficiaries, with CHD being the primary cause of heart attacks. In 2022 alone, CHD claimed 371,506 lives in the United States. A favorable pricing determination could significantly enhance access to these cutting-edge diagnostic tools for millions of Medicare patients, potentially leading to earlier detection and more effective management of CHD.
For Cardio Diagnostics, a positive outcome could accelerate the commercial success of its tests and solidify its position in the cardiovascular diagnostics market. The company's approach, which combines genetic and epigenetic analysis with artificial intelligence, represents a new frontier in personalized cardiovascular medicine. The integration of these tests with the Actionable Clinical Intelligence provider-facing platform further enhances their potential impact on patient care.
As the healthcare industry continues to move towards more personalized and preventive approaches, the CMS decision on Cardio Diagnostics' tests could serve as a bellwether for the adoption of AI-driven diagnostic tools in Medicare coverage. This decision may also influence private insurers' policies, potentially broadening access to these advanced diagnostics across the healthcare system.
The anticipated CMS announcement this month marks a critical juncture for Cardio Diagnostics and the field of cardiovascular medicine. It underscores the growing recognition of the role that AI and precision diagnostics can play in addressing one of the most pressing health challenges facing the aging population. As the healthcare community awaits the decision, the potential for these tests to revolutionize CHD prevention and management remains at the forefront of discussions on the future of cardiovascular care.
Curated from News Direct
